C4 Therapeutics (NASDAQ: CCCC) CMO receives 240,000 RSUs and reports tax share withholding

Rhea-AI Filing Summary

C4 Therapeutics Chief Medical Officer Leonard Reyno reported multiple equity compensation transactions in company stock. On February 13, 2026, he received a grant of 240,000 restricted stock units (RSUs), with 120,000 RSUs vesting in three equal annual installments starting on February 13, 2027, and 120,000 RSUs vesting in full on February 13, 2029, subject to potential performance-based acceleration.

On February 14, 2026, previously disclosed RSU awards vested, resulting in the acquisition of 30,950 shares of common stock at no cost. On the same date, 16,579 shares were withheld by the company at $1.89 per share to cover tax obligations related to the RSU vesting, which the filing states does not represent a sale. Following these transactions, Reyno directly owned 379,803 shares of common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

REYNO LEONARD

(Last) (First) (Middle)

C/O C4 THERAPEUTICS, INC.

490 ARSENAL WAY #120

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		A		240,000(1)	A	$0	396,382	D
Common Stock	02/14/2026		M(2)	V	30,950	A	$0	396,382	D
Common Stock	02/14/2026		F(3)		16,579	D	$1.89	379,803	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 120,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 120,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.

2. Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 14, 2024 and February 18, 2025.

3. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.

Remarks:

	/s/ Shagha Russell, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did C4 Therapeutics (CCCC) grant to its CMO Leonard Reyno?

C4 Therapeutics granted Leonard Reyno 240,000 restricted stock units (RSUs). 120,000 RSUs vest in three equal annual installments from February 13, 2027, and 120,000 RSUs vest in full on February 13, 2029, with potential performance-based acceleration.

How many C4 Therapeutics (CCCC) shares did Leonard Reyno acquire through RSU vesting?

Leonard Reyno acquired 30,950 shares of C4 Therapeutics common stock upon RSU vesting on February 14, 2026. These shares came from previously disclosed RSU grants and were received at $0.00 per share as part of his equity compensation.

Were any of Leonard Reyno’s C4 Therapeutics (CCCC) Form 4 transactions open-market sales?

No, the Form 4 states that 16,579 shares were withheld by C4 Therapeutics at $1.89 per share solely to satisfy tax withholding obligations. The filing clarifies this does not represent a sale by Leonard Reyno in the market.

What is Leonard Reyno’s share ownership in C4 Therapeutics (CCCC) after these transactions?

After the reported transactions, Leonard Reyno directly owned 379,803 shares of C4 Therapeutics common stock. This reflects the RSU grant, RSU vesting, and the company’s share withholding for taxes described in the Form 4 filing.

What are the vesting terms for Leonard Reyno’s new RSUs at C4 Therapeutics (CCCC)?

The new 240,000 RSUs vest in two structures: 120,000 RSUs vest in three equal annual installments starting February 13, 2027, and 120,000 RSUs vest fully on February 13, 2029, with possible acceleration if certain performance milestones are achieved.

What do the Form 4 footnotes explain about C4 Therapeutics (CCCC) RSU awards?

The footnotes explain that the reported RSUs each represent a right to receive one share upon vesting, detail the time-based and performance-based vesting schedule, identify the 30,950-share acquisition as RSU vesting, and clarify that 16,579 withheld shares were for taxes, not a discretionary sale.